Abstract | BACKGROUND: RESULTS:
Romiplostim was well-tolerated and administration was associated with an increase in platelet counts in all five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3-10 months. CONCLUSIONS:
Romiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may help to develop and use new therapeutics for ITP in dogs and humans.
|
Authors | Barbara Kohn, Gürkan Bal, Aleksandra Chirek, Sina Rehbein, Abdulgabar Salama |
Journal | BMC veterinary research
(BMC Vet Res)
Vol. 12
Pg. 96
(Jun 10 2016)
ISSN: 1746-6148 [Electronic] England |
PMID | 27283401
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Receptors, Fc
- Receptors, Thrombopoietin
- Recombinant Fusion Proteins
- Thrombopoietin
- romiplostim
|
Topics |
- Animals
- Dog Diseases
(drug therapy)
- Dogs
- Receptors, Fc
(therapeutic use)
- Receptors, Thrombopoietin
(antagonists & inhibitors)
- Recombinant Fusion Proteins
(therapeutic use)
- Thrombocytopenia
(drug therapy, veterinary)
- Thrombopoietin
(therapeutic use)
|